Nanospectra Biosciences, Inc. Names John Stroh New CEO

HOUSTON, TX--(Marketwire - August 08, 2011) - Health-care industry veteran and experienced financial and operational leader John Stroh has been named the new President and CEO of Nanospectra Biosciences, Inc. of Houston, Texas.

Stroh replaces former CEO J. Don Payne, who is pursuing other opportunities in the Medical sector after 9 years with Nanospectra.

“Nanospectra Biosciences is on the cutting edge of a new model in cancer treatment,” said David Anderson, Chairman of the Board for Nanospectra. “We are now entering our next stage of growth and are delighted to have a leader of John’s caliber and breadth of experience in medical technology to lead our company into the future. His years of dedicated service at similar cancer technology companies will be invaluable as we continue to evolve our clinical research into bedside patient care.”

Stroh most recently served as interim CEO for CryoFem, a Cryoablation company focused in Womens Health. Prior to that, he was CEO of NeoMatrix, an innovative developer of medical devices developed for the assessment of Breast Cancer risk in Irvine, California. In his position, Stroh increased sales by more than 400 percent while reducing expenses by nearly 20 percent, production costs by nearly 25 percent and facility costs by more than 20 percent over a three year period.

Prior to his time at NeoMatrix, Stroh served as chief operations officer, chief financial officer and senior vice president of business development at Kadmus Pharmaceuticals in Irvine. While at Kadmus, he headed up the development of multi-functional operations, including finance, operations and business development. He was also on the board of Directors of Kadmus Pharmaceuticals LTD, the Canadian subdivision of Kadmus Pharmaceuticals, Inc. While at Kadmus Stroh was instrumental in the origination and structuring of the asset sale of the company to Organon Biosciences (now part of Merck Inc).

“Nanospectra’s role as a leader in the development of innovative cancer treatments has been charted,” said Stroh. “I feel honored and privileged to join this amazing team of health-care professionals and to build on the legacy Nanospectra has created.”

The developers of a unique particle-based therapy for the precise destruction of solid tumors, Nanospectra Biosciences, Inc. exclusively holds eleven US patents covering the technology. The benefits of Nanospectra’s unique approach are: precise elimination of irregularly shaped or invasive tumors, the potential treatment of otherwise non-resectable tumors, and the avoidance of significant damage to surrounding healthy tissue.